Drugs / LX-039
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04097756 | Jan 2020 → Aug 2022 | female breast carcinoma | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-23 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Results 罗欣药业抗肿瘤创新药LX-039片I期临床研究数据亮相2023 ESMO luoxin.cn ↗
共4例受试者达到部分缓解，客观缓解率10.8%，24周临床获益率40%。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-23 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 罗欣药业抗肿瘤创新药LX-039片I期临床研究数据亮相2023 ESMO luoxin.cn ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX-039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04097756 ↗ |
| Action | Inhibit | “desirable ER antagonistic characteristics” PMID 35436589 ↗ Apr 2022 |
| Modality | Small molecule | “Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).” PMID 35436589 ↗ Apr 2022 |
| Route | Oral | “LX-039 tablets,which can be administered orally” NCT04097756 ↗ |